Galzitskaya Oxana V
Laboratory of Bioinformatics and Proteomics, Institute of Protein Research, Russian Academy of Sciences, Pushchino, Russia.
Laboratory of the Structure and Function of Muscle Proteins, Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino, Russia.
Front Mol Neurosci. 2020 Jan 31;12:319. doi: 10.3389/fnmol.2019.00319. eCollection 2019.
Currently, there is no effective treatment of proteinopathies, as well as their diagnosis in the early stages of the disease until the first clinical symptoms appear. The proposed model of fibrillation of the Aβ peptide and its fragments not only describes molecular rearrangements, but also offers models of processes that occur during the formation of amyloid aggregates. Since this model is also characteristic of other proteins and peptides, a new potential target for drug development in the treatment of Alzheimer's disease (AD) and other proteinopathies is proposed on the basis of this model. In our opinion, it is oligomers that are promising targets for innovative developments in the treatment of these diseases.
目前，对于蛋白质病尚无有效的治疗方法，在疾病早期直至出现首个临床症状之前也无法进行诊断。所提出的Aβ肽及其片段的纤维化模型不仅描述了分子重排，还提供了淀粉样聚集体形成过程中发生的过程模型。由于该模型对其他蛋白质和肽也具有特征性，因此基于此模型提出了治疗阿尔茨海默病（AD）和其他蛋白质病的药物开发新潜在靶点。我们认为，寡聚体是这些疾病治疗创新发展的有前景的靶点。
